Avatrombopag [CAS 570406-98-3]

Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM) . Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

[570406-98-3]

C29H34Cl2N6O3S2

649.65

O=C(C1CCN(C2=NC=C(C(NC3=NC(C4=CC(Cl)=CS4)=C(N5CCN(C6CCCCC6)CC5)S3)=O)C=C2Cl)CC1)O

Thrombopoietin Receptor

10mM

99.83

DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H314

H314